Tashkent, Uzbekistan (UzDaily.uz) — The International Testing Agency (ITA) has reported adverse analytical findings in doping samples from two athletes representing Uzbekistan — canoeist Pavel Eigel and mixed martial arts athlete Nodirbek Shavkatov. The report was issued by the ITA on behalf of the Olympic Council of Asia (OCA).
Trimetazidine was detected in Pavel Eigel’s sample. The sample was collected by the ITA in Japan on 23 September 2026 as part of out-of-competition anti-doping testing.
Trimetazidine is included in the World Anti-Doping Agency (WADA) Prohibited List under category S4, “Hormone and Metabolic Modulators.” The substance is prohibited both in and out of competition and is classified as a non-specified substance.
According to the ITA, Eigel was notified of the case and provisionally suspended pending its resolution in accordance with the World Anti-Doping Code and the OCA Anti-Doping Rules. During the provisional suspension, the athlete is barred from participating in competitions, training, coaching activities and other events related to the Aichi-Nagoya 2026 Asian Games.
The second case concerns Nodirbek Shavkatov, who competed in modern MMA in the up-to-71 kg weight category. Meldonium was detected in his sample, which was collected in Japan on 22 September 2026 as part of out-of-competition testing.
Shavkatov was also notified of the case and provisionally suspended in accordance with the World Anti-Doping Code and the OCA Anti-Doping Rules.
Meldonium is included in category S4, “Hormone and Metabolic Modulators,” of the WADA Prohibited List. Like trimetazidine, it is prohibited at all times and is classified as a non-specified substance.
At the Aichi-Nagoya 2026 Asian Games, Shavkatov won a bronze medal in modern MMA. He lost to Kazakhstan’s Kadybek Shinbayev in the semifinals.
Both athletes have the right to challenge the imposition of provisional suspension before the Anti-Doping Division of the Court of Arbitration for Sport (CAS ADD). They may also request analysis of their B samples.
The ITA separately noted that an adverse analytical finding refers to a test result indicating the presence of a prohibited substance or its metabolites or markers in a sample in accordance with the requirements of the relevant international standards.
As the proceedings are ongoing, the ITA said it would not provide further comments on the cases at this stage.
